The FDA had resolved the shortage of Wegovy in April, and telehealth providers were advised to stop selling compounded ...

JPMorgan analyst Daniel Politzer initiated coverage of MGM Resorts (MGM) with a Neutral rating and $38 price target The firm says land-based U.S.

Shares in both companies were down following news of the second death, casting fresh safety concerns over Elevidys.